Pulmonary embolism (PE) is a rather common cardiovascular disorder constituting one of the major manifestations of venous thromboembolism (VTE). It is associated with high mortality and substantial recurrence rates, and its diagnosis may be challenging, especially in patients with respiratory comorbidities. Therefore, providing a prompt and accurate diagnosis for PE through developing highly sensitive and specific diagnostic algorithms would be of paramount importance. There is sound evidence supporting the use of biomarkers to enhance the diagnosis and predict the recurrence risk in patients with PE. Therefore, several novel biomarkers, such as factor VIII, Ischemia Modified Albumin, and fibrinogen, as well as several MicroRNAs and microparticles, have been investigated for the diagnosis of this clinical entity. The present review targets to comprehensively present the literature regarding the novel diagnostic biomarkers for PE, as well as to discuss the evidence for their use in daily routine.
Ureteral complications remain a significant cause of morbidity following kidney transplantation and may threaten graft survival if not diagnosed promptly. Retrograde multidetector computed tomography (MDCT) urography has emerged as a valuable imaging modality for detailed evaluation of the transplant ureter. This case series highlights the role of retrograde MDCT urography in the assessment of post-transplant ureteral complications, particularly urine leaks and ureteral obstructions, in patients with inconclusive or non-diagnostic ultrasound findings. In the presented cases, retrograde MDCT urography accurately localized the site and extent of ureteral leaks, facilitated timely therapeutic decision-making, and contributed to preservation of graft function. The technique provided high spatial resolution and comprehensive anatomical visualization of the collecting system and ureter. These observations support the role of retrograde MDCT urography as a reliable and effective adjunct imaging modality of the diagnostic algorithm for renal transplant recipients with suspected urological complications.